Fingolimod Hydrochloride

sphingosine kinase 1 ; Homo sapiens







13 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 35158767 Sphingosine Kinase-1 Is Overexpressed and Correlates with Hypoxia in Osteosarcoma: Relationship with Clinicopathological Parameters. 2022 Jan 19 1
2 34549307 SPHK1 contributes to cisplatin resistance in bladder cancer cells via the NONO/STAT3 axis. 2021 Nov 1
3 35237148 SPHK Inhibitors and Zoledronic Acid Suppress Osteoclastogenesis and Wear Particle-Induced Osteolysis. 2021 1
4 33035646 Structure-function analysis of lipid substrates and inhibitors of sphingosine kinases. 2020 Dec 1
5 28695300 New FTY720-docetaxel nanoparticle therapy overcomes FTY720-induced lymphopenia and inhibits metastatic breast tumour growth. 2017 Oct 2
6 26673009 Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression. 2016 Jan 19 1
7 27001955 Topical Application of Fingolimod Perturbs Cutaneous Inflammation. 2016 May 1 1
8 24657936 Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro. 2014 Jun 1 2
9 25109763 FTY720 and cisplatin synergistically induce the death of cisplatin-resistant melanoma cells through the downregulation of the PI3K pathway and the decrease in epidermal growth factor receptor expression. 2014 Oct 1
10 21464128 FTY720 analogues as sphingosine kinase 1 inhibitors: enzyme inhibition kinetics, allosterism, proteasomal degradation, and actin rearrangement in MCF-7 breast cancer cells. 2011 May 27 1
11 21912422 Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer. 2011 Sep 13 3
12 20570726 FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells. 2010 Oct 2
13 13129923 Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. 2003 Nov 28 1